{"denoms":[{"counts":[{"groupId":"BG000","value":"63"}],"units":"Participants"}],"groups":[{"description":"bortezomib and rituximab\n\nBortezomib: Once weekly for 3 weeks\n\nRituximab: Intravenously once a week for the first and fourth weeks of a cycle","id":"BG000","title":"Bortezomib and Rituximab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"36"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"43","upperLimit":"86","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"41"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}